EP0644754A1 - Substance pouvant arreter le saignement dans des applications chirurgicales, medicales et dentaires/substance sous forme de poudre 001 pouvant arreter le saignement en chirurgie, post-chirurgie, medecine, dentisterie ou toute hemorragie provoquee par des causes diverses - Google Patents

Substance pouvant arreter le saignement dans des applications chirurgicales, medicales et dentaires/substance sous forme de poudre 001 pouvant arreter le saignement en chirurgie, post-chirurgie, medecine, dentisterie ou toute hemorragie provoquee par des causes diverses

Info

Publication number
EP0644754A1
EP0644754A1 EP92901379A EP92901379A EP0644754A1 EP 0644754 A1 EP0644754 A1 EP 0644754A1 EP 92901379 A EP92901379 A EP 92901379A EP 92901379 A EP92901379 A EP 92901379A EP 0644754 A1 EP0644754 A1 EP 0644754A1
Authority
EP
European Patent Office
Prior art keywords
bleeding
powder
surgery
photograph
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92901379A
Other languages
German (de)
English (en)
Other versions
EP0644754A4 (fr
Inventor
Leslie Binshyang Soong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0644754A1 publication Critical patent/EP0644754A1/fr
Publication of EP0644754A4 publication Critical patent/EP0644754A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof

Definitions

  • the substance powder 001 that can stop (stanch) bleeding in surgical, postsurgical, medical and dental uses or any bleeding due to any causes by topical administration or the substance powder 001 that has very potent hemostatic action can be administered topically to stop bleeding during surgery, after surgery, medicine by ingestion, dental surgery, extraction of teeth, and any injury or due to any causes for any normal and pathological persons.
  • Tattersal and Seville 1950 reported purpura in 60 out of 809 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and forearms. and on the backs of their hands, noth patients. and the controls were ascorbate deficient, as judged by ascorbic acid loading tests; skin biopsies from those with purpura showed degeneration of the collagen fibres of the dermis.
  • THIS invention pertains to the field of disorder of hemostasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboembolic disorders.
  • the blood coagulation mechanism of ascorbi c acid which was administered topically does not fall into either
  • the present methods available to stop bleeding in surgery are cautery, epinephrine injection, pressure and some fiber foam.
  • the cautery can cause tissue necrosis in
  • the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly w el l for diffuse capillary bleeding and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency of the kinds of aforementioned patients.
  • the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRNA in the regulation of col l agen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
  • Substance powder 001 represents ascorbic acid powder that is obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding when spraying it topically on the bleeding a rea for any
  • hemophilia blood needs 0.1568 g of ascorbic acid powder.
  • Sufficient substance powder 001 is particularly useful to help stop bleeding in the case of diffuse capillary oozing and mistakenly cut off artery or arteries that cannot be found during massive bleeding bleeding so as to save the patients' lives.
  • the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, pressure and some fiber foam.
  • the cautery can cause tissue necrosis in some cases.
  • the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capi l l ary oozing patients, while ascorbic acid powder does not cause any tissue necrosis and particularly works well for diffuse capillary bleeding and oozing and any traditionally uncontrollable bleeding tendency patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
  • the ascorbic acid also facilitate wound healing ( Oral Surg.
  • the substance powder 001 is made by grinding the pure vitamin C tablets into powder.
  • the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this vitamin C powder to coagulate 1 ml of human blood. This is the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this situation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows:
  • Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
  • Photograph # 1 massive bleeding when the femoral artery is cut off
  • Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into
  • the amount of the powder needed is proportional to the amount of blood coming out of the vessel.
  • Photograph # 3 In the case of capillary bleeding
  • This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
  • the operation of stopping bleeding consists of combining the powder with press with gauze.
  • those that look black in color indicate the black blood coagulation ( Photograph # 14), while those that are white in color are those the powder does not get mixed up with the blood ( Photograph # 15).
  • Photograph # 16 At the end of the operation, most of black blood coagulation was wiped out with 4x4 gauze, and rinsed with Ringer's solution ( Photograph # 16 ). It took totally 5 minutes to stop the bleeding completely. The patient's conditions are especially well, better than without using this powder.
  • Photograph # 17 When the skin graft is removed from the hand,massive bleeding occurs ( Photograph # 17) . On applying sufficient powder to the bleeding area topically, it appears black coagulation within one second. Bleeding stops nt the same time ac the black coagulation forms. Those that appears white indicate the powder not yet mixed up with the blood. ( Photograph 4 18); those that appears more black area indicate the more powder mixed up with the blood (Photograph # 19), Suture going on ( Photograph # 20 ) Case 4. Age 70, female, paraanal abscess excision, bleeding when it is opened up ( Photograph # 21 ). When spraying the powder to the bleeding area, it stop bleeding by forming black blood coagulation immediately. Those that appears white are the powder that are not mixed up with the blood. ( Photograph # 212), Suture going on ( Photograph # 23 ).
  • Photograph # 24 On spraying the powder topically to the bleeding area, the black color is formed immediately because of the blood coagulation ( Photograph # 25 ) .
  • the white color is the powder instantly not mixed up with the blood yet. ( Photograph # 25 ), lastly, insert the long gauze into the anus. ( Photograph # 27 )
  • Photograph # 29 Wipe out the black coagulation in 10 seconds, stop bleeding still persisted ( Photograph # 30 )
  • blood requires 0.1568 g of powder to form black blood coagulation by shaking the tube with hand or stirer machine.
  • Nan Tze District, Kaohsiung City lastly, Stops bleeding in tonsillectomy rat within one second by topical use of this (f). Claims of Utilities of ascorbic acid powder.
  • this powder topically in to her bleeding nostril.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention décrit un procédé servant à arrêter les saignements. Le procédé comprend l'application de vitamine C en poudre sur l'emplacement du saignement.
EP92901379A 1990-12-06 1991-12-05 Substance pouvant arreter le saignement dans des applications chirurgicales, medicales et dentaires/substance sous forme de poudre 001 pouvant arreter le saignement en chirurgie, post-chirurgie, medecine, dentisterie ou toute hemorragie provoquee par des causes diverses. Withdrawn EP0644754A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62409490A 1990-12-06 1990-12-06
US624094 1990-12-06
PCT/US1991/009201 WO1992010999A1 (fr) 1990-12-06 1991-12-05 Substance pouvant arreter le saignement dans des applications chirurgicales, medicales et dentaires/substance sous forme de poudre 001 pouvant arreter le saignement en chirurgie, post-chirurgie, medecine, dentisterie ou toute hemorragie provoquee par des causes diverses

Publications (2)

Publication Number Publication Date
EP0644754A1 true EP0644754A1 (fr) 1995-03-29
EP0644754A4 EP0644754A4 (fr) 1995-12-27

Family

ID=24500629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92901379A Withdrawn EP0644754A4 (fr) 1990-12-06 1991-12-05 Substance pouvant arreter le saignement dans des applications chirurgicales, medicales et dentaires/substance sous forme de poudre 001 pouvant arreter le saignement en chirurgie, post-chirurgie, medecine, dentisterie ou toute hemorragie provoquee par des causes diverses.

Country Status (5)

Country Link
EP (1) EP0644754A4 (fr)
AU (1) AU662505B2 (fr)
CA (1) CA2095439C (fr)
NO (1) NO930858D0 (fr)
WO (1) WO1992010999A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (fr) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice ou produit similaire
DE2808572A1 (de) * 1977-03-04 1978-09-07 Shiraimatsu Shinyaku Co Haemostatisches mittel
WO1987006465A1 (fr) * 1986-04-22 1987-11-05 Olav Johan Braenden Kit anti-rhume, preparation anti-rhume et leur utilisation
WO1990012572A1 (fr) * 1989-04-17 1990-11-01 Duke University Compositions stables d'acide ascorbique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1334933A (en) * 1971-02-19 1973-10-24 Ahrens G W Reaction products of caldium ascorbate and preparation containing them
US4959362A (en) * 1983-12-19 1990-09-25 Takeda Chemical Industries, Inc. Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system
US5021452A (en) * 1989-01-09 1991-06-04 The Board Of Regents Of The University Of Washington Process for enhancing wound healing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2336925A1 (fr) * 1975-12-30 1977-07-29 Mouney Guy Dentifrice ou produit similaire
DE2808572A1 (de) * 1977-03-04 1978-09-07 Shiraimatsu Shinyaku Co Haemostatisches mittel
WO1987006465A1 (fr) * 1986-04-22 1987-11-05 Olav Johan Braenden Kit anti-rhume, preparation anti-rhume et leur utilisation
WO1990012572A1 (fr) * 1989-04-17 1990-11-01 Duke University Compositions stables d'acide ascorbique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE 165317 GURNEY B.F. 'Hemostatic Agents' & ORAL HYG., vol.56, no.7, 1966 pages 78 - 80 *
POL TYG LEK (POLAND), NOV 20 1972, VOL. 27, NO. 47, PAGE(S) 1861-2, Antoszewski Z 'Zastosowanie preparatu Cepevit-K do tamowania krwawien i krwotokow po usunieciu zebow.' *
See also references of WO9210999A1 *

Also Published As

Publication number Publication date
EP0644754A4 (fr) 1995-12-27
AU9103491A (en) 1992-07-22
AU662505B2 (en) 1995-09-07
CA2095439C (fr) 1998-12-08
WO1992010999A1 (fr) 1992-07-09
CA2095439A1 (fr) 1992-06-07
NO930858D0 (no) 1993-03-09

Similar Documents

Publication Publication Date Title
JPS6069028A (ja) インシユリンを含む薬剤組成物
Muir Text-book of Pathology
Redding Thrombocythemia as a cause of erythermalgia
JPH04149126A (ja) 経粘膜投与用医薬組成物
FR2491475A1 (fr) Procede de preparation de sulfate de chondroitine et composition pharmaceutique contenant ce dernier
RU2376993C2 (ru) Применение тимосапонина вii при получении лекарственного средства или продукта для профилактики и лечения инсульта
AU662505B2 (en) Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes
Collens et al. The use of intermittent venous compression in the treatment of peripheral vascular disease: A preliminary report
CN104784193B (zh) 一种原人参二醇型三七皂苷的制药用途
Diamond et al. Kwashiorkor in a North American white male
US6783774B1 (en) Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses
Witkind et al. APLASIA OF THE BONE MARROW DURING MESANTOIN® THERAPY: REPORT OF A FATAL CASE
Vaughan et al. Skin necrosis of genitalia and warfarin therapy
JP2009191015A (ja) 創傷治癒促進剤
Collings et al. Three cases of inoculation of tuberculosis from tattooing
Chandler et al. Benign duodeno-colonic fistula
Clements Manifestations of nutritional deficiency in infants
RU2142271C1 (ru) Способ профилактики местных и общих постишемических осложнений при длительной компрессионной травме конечности
CN106806378B (zh) 三七皂苷Fc的制药用途
Burt Anticoagulants
Krishna Study of Surgincal Complicatons in Diabetic Patients Among The Rural Population
Pederson Physiology and treatment of severe burns: with special reference to burn shock
RU2228194C2 (ru) Средство, предотвращающее развитие геморрагического, кровесвертывающего и отчетно-некротического действия яда змеи при отравлении им организма
Smith Laparoscopic cholecystectomy.
DE3546360A1 (de) Verwendung von desoxycholsaeure bei wundheilungsstoerungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950626

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE

17Q First examination report despatched

Effective date: 19980803

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19980803

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APBX Invitation to file observations in appeal sent

Free format text: ORIGINAL CODE: EPIDOSNOBA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

18D Application deemed to be withdrawn

Effective date: 20050701